Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori

NCT06751121 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

461

Enrollment

INDUSTRY

Sponsor class

Conditions

Helicobacter Pylori Infection
Helicobacter Pylori Infected Patients
Helicobacter Pylori Infected Subjects

Interventions

DRUG: DWP14012 40mg
DRUG: DWC202301 30mg
DRUG: Amoxicillin 1000mg
DRUG: Clarithromycin 500mg
DRUG: DWC202301 30mg placebo
DRUG: DWP14012 40mg placebo

Sponsor

Daewoong Pharmaceutical Co. LTD.